Accelerate your Program

Fastest to patients

AxelaRx’s Accelerator Program is designed to accelerate novel technologies and intellectual property from the industry and academia. It delivers up to 50% faster time to market for our portfolio companies by accelerating the path from discovery through clinical trials all the way to commercialization. The program advances innovative technologies on three main areas to ensure the fastest way to the market.

Funding and strategic collaboration
In-house CRO
A worldwide network

The right match for funding
and strategic collaborations

An efficient drug development process goes hand in hand with dependable partner relationship. In turn, sufficient monetary resources that support the smooth transitions from phase to phase are also vital. Through AxelaRx we will introduce you to the most promising investors and strategic partners that match your values and goals. We will provide you with guidance where necessary to ensure the right match for you.

Accelerate your technology
with our in-house CRO

At AxelaRx we follow a fastest-to-patients approach in which immediate support of drug development and clinical processes is key. That is why we have our own in-house unique molecular imaging CRO TRACER.

Through TRACER we offer you years of validated experience in clinical translation of novel proprietary compounds, applying molecular imaging techniques and the FDA approved in-human microdosing approach. This cuts down:

• Your drug development time by up to 50%
• Your drug development costs by up to 50%

A worldwide network
within your reach

An extensive network of world-renowned scientists, research institutes, clinicians, investors, industry veterans and regulatory advisors in the USA and Europe are ready to support you in your efforts. Being part of the Accelerator Program provides you with full access to this state-of-the-art global network. This supportive critical mass is able to add impactful value to your venture quickly. It also enables faster clinical translation, market access and Merger & Acquisitions.

Meet our portfolio companies

Fighting cancer beyond the cutting edge

Invisible tumor cells often migrate beyond the edge of the primary tumor. Exotome Inc. is developing a dual-purpose theranostic agent that fluoresces in real-time, optimizing curative surgery results, and simultaneously ablates migrating tumor cells on a molecular level.

Nerve imaging to improve surgical outcomes

AVAX is a strategic partnership between Avelas Biosciences Inc and AxelaRx to accelerate the development of promising nerve imaging agents. Unwanted nerve damage is a serious complication that may occur during a variety of surgical procedures. Therefore, intraoperative fluorescent visualization of nerves is a significant unmet medical need for surgeons and novel approaches, such as AVB-N-311 and AVB-N-312, have the potential to greatly improve surgical outcomes for patients. AVB-N-311 and AVB-N-312 are proprietary fluorescent nerve imaging agents discovered and developed by Avelas.

Read more about the partnership

Meet our Accelerator Advisor team

Gerrit is a seasoned pharma executive at Novartis, with previous roles in development and medical affairs in North America, Asia and Europe. He is leading teams to advance science across many disease areas and implement innovative therapies in healthcare systems. Gerrit brings years of experience and a true understanding and insights of what it takes to successfully develop a biotech venture in the current Life Sciences market.

Find out more about Gerrit and his passion for Life Sciences here.

Willem is an executive level proven innovator in large international blue chip companies as well as a successful operator in early and growth stage healthcare and technology businesses. Known for his passionate and encouraging leadership approach to build high performance teams, Willem enjoys an international reputation for finding and extracting value from new products and business models.

Find out more about Willem and his experience in the Life Sciences industry here.

As Medical Director of the Stanford Cancer Center, Dr. Rosenthal has overseen the clinical delivery of cancer care across Stanford Medicine and regional cancer networks. He is clinically active in microvascular reconstruction of complex head and neck defects. As a surgeon-scientist, he is engaged in conducting early-phase clinical trials for diagnostic and therapeutic agents in the treatment of solid tumors in head and neck cancer, as well as brain tumors, lung cancer and pancreatic cancer.

Prof. Feringa obtained his PhD at the University of Groningen, where he was appointed full professor in 1988. His discovery of the molecular motor ranks highly among the many discoveries made over the years. In 2016 prof. Feringa was awarded the Nobel Prize for Chemistry, together with Jean-Pierre Sauvage and Sir James Fraser Stoddart.

Professor of Radiology and Biomedical Engineering at Case Western Reserve served in various positions at the NIH, Harvard Medical School/MGH, and  Variagenics Inc. Prof. Basilion is the immediate past-president of the World Molecular Imaging Society.

A former scientist-turned-communication pro, Giuseppe has over 20 years of experience in the biopharmaceutical industry. He has worked with some of the most innovative companies in the sector, from startups to big corporations (e.g., Johnson & Johnson). Giuseppe is the founder of Chiaro, a pitch & presentation agency dedicated to the Health & Life Sciences. At Chiaro, his mission is to help CEOs and founders to turn their science into an irresistible story – to generate funding, growth, and success for their organizations.

Find out more about Giuseppe and his look on storytelling in the Life Sciences here.